DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that Company executives will not be presenting at the following investor conferences in order to focus on activities leading to the Lymphoseek NDA resubmission.
